Novozymes A/S Presents at SEB NASDAQ OMX Nordic Market Day, May-16-2013 . Venue: The NASDAQ MarketSite, NASDAQ Tower, 4 Times Square, New York, NY 10036, United States. Speakers: Thomas Bomhoff, Head of IR.

Novozymes A/S announced unaudited consolidated earnings results for the first quarter of 2013. For the period, the company reported revenue of DKK 2,845 million against DKK 2,734 million a year ago. EBITDA was DKK 884 million against DKK 855 million a year ago. Operating profit /EBIT was DKK 709 million against DKK 680 million a year ago. Profit before tax was DKK 661 million against DKK 658 million a year ago. Net profit was DKK 514 million against DKK 510 million a year ago. Diluted earnings per were DKK 1.62 against DKK 1.59 a year ago. Free cash flow before acquisitions was DKK 82 million against DKK 456 million a year ago. Return on equity was 21.4% against 23.4% a year ago. Profit attributable to shareholders of the company was DKK 514 million against DKK 509 million a year ago. Cash flow from operating activities was DKK 260 million against DKK 614 million a year ago. Purchase of intangible assets was DKK 5 million against DKK 3 million a year ago. Purchase of property, plant and equipment was DKK 173 million against DKK 155 million a year ago. Net debt close to DKK 1 billion on the same period compared to last year. ROIC was 18.6% against 20.9% a year ago. For the full year 2013, company increases the expectation for sales growth in DKK to 5-8%, up from 4-7% at previous guidance. EBIT growth to be in the range of 4-7%. Net profit growth to be in the range of 6-9%. Free cash flow before acquisitions of DKK 1,650 million. ROIC to be in the range of 19% to 20%.

Novozymes A/S Presents at Bloomberg New Energy Finance Summit, Apr-22-2013 02:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Peder Holk Nielsen, Chief Executive Officer and President.